FDA warned NeuroHydrate that its HM-FORMULA supplement is an unapproved new drug because website claims say it prevents migraine.
What happened
In January 2021, FDA reviewed NeuroHydrate's website and found it took orders for HM-FORMULA. The site claimed the product was designed for headache and migraine prevention and to reduce migraine frequency, severity, and duration. FDA said these claims make it a drug, and because it is not generally recognized as safe and effective for those uses, it is a new drug (a product requiring FDA approval before sale) sold without approval.
What FDA found
Website claims say HM-FORMULA is intended to prevent, reduce, or treat headache and migraine, which makes it a drug.
Section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]The product is not generally recognized as safe and effective for the claimed headache and migraine uses, so it is a new drug.
Section 201(p) of the Act [21 U.S.C. 321(p)]The company introduced or delivered the unapproved new drug into interstate commerce without FDA approval.
Sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]
What FDA wants
FDA asks NeuroHydrate to notify it in writing within 15 working days of the steps taken to correct the violations and prevent recurrence. If the company believes it is not violating the Act, it must include its reasoning and supporting information; if corrections will take longer, it must explain the delay and completion date.
Who should pay attention
- dietary supplement brands that make disease claims
- e-commerce and marketing teams writing product claims
- companies selling migraine or headache supplements
This is a summary. Read the original letter on fda.gov.